Literature DB >> 18160442

Combination of an antiviral drug and immunomodulation against hepadnaviral infection in the woodchuck model.

Mengji Lu1, Xin Yao, Yang Xu, Heike Lorenz, Uta Dahmen, Haidong Chi, Olaf Dirsch, Thekla Kemper, Lifang He, Dieter Glebe, Wolfram H Gerlich, Yumei Wen, Michael Roggendorf.   

Abstract

The essential role of multispecific immune responses for the control of hepatitis B virus (HBV) infection implies the need of multimodal therapeutic strategies for chronic HBV infection, including antiviral chemotherapy and immunomodulation. This hypothesis was tested in the woodchuck model by a combination of lamivudine pretreatment and subsequent immunizations of woodchucks chronically infected with woodchuck hepatitis virus. The immunizations were performed with DNA vaccines or antigen-antibody immune complexes (IC)/DNA vaccines. Immunizations with IC/DNA vaccines led to an anti-woodchuck hepatitis virus surface antibody response and significant reductions of viral load and antigenemia, suggesting that such a strategy may be effective against chronic HBV infection.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18160442      PMCID： PMC2258919          DOI： 10.1128/JVI.01613-07

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  45 in total

1.  Vaccination with recombinant HBsAg-HBIG complex in healthy adults.

Authors:  Dao-Zhen Xu; Ke-Lin Huang; Kai Zhao; Li-Feng Xu; Nan Shi; Zheng-Hong Yuan; Yu-Mei Wen
Journal:  Vaccine       Date:  2005-04-08       Impact factor: 3.641

Review 2.  Cellular and virological mechanisms of HBV drug resistance.

Authors:  Stephen Locarnini; William S Mason
Journal:  J Hepatol       Date:  2005-12-07       Impact factor: 25.083

3.  Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients.

Authors:  Xin Yao; Bojian Zheng; Jie Zhou; Dao-Zhen Xu; Kai Zhao; Shu-Hui Sun; Zheng-Hong Yuan; Yu-Mei Wen
Journal:  Vaccine       Date:  2006-11-27       Impact factor: 3.641

4.  Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.

Authors:  Harry L A Janssen; Monika van Zonneveld; Hakan Senturk; Stefan Zeuzem; Ulus S Akarca; Yilmaz Cakaloglu; Christopher Simon; Thomas M K So; Guido Gerken; Robert A de Man; Hubert G M Niesters; Pieter Zondervan; Bettina Hansen; Solko W Schalm
Journal:  Lancet       Date:  2005 Jan 8-14       Impact factor: 79.321

5.  Immunization with the gene expressing woodchuck hepatitis virus nucleocapsid protein fused to cytotoxic-T-lymphocyte-associated antigen 4 leads to enhanced specific immune responses in mice and woodchucks.

Authors:  Mengji Lu; Masanori Isogawa; Yang Xu; Gero Hilken
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

6.  Intrahepatic CD8+ T-lymphocyte response is important for therapy-induced viral clearance in chronic hepatitis B infection.

Authors:  Thjon J Tang; Jaap Kwekkeboom; Shanta Mancham; Rekha S Binda; Robert A de Man; Solko W Schalm; Johannes G Kusters; Harry L A Janssen
Journal:  J Hepatol       Date:  2005-04-25       Impact factor: 25.083

7.  Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

Authors:  George K K Lau; Teerha Piratvisuth; Kang Xian Luo; Patrick Marcellin; Satawat Thongsawat; Graham Cooksley; Edward Gane; Michael W Fried; Wan Cheng Chow; Seung Woon Paik; Wen Yu Chang; Thomas Berg; Robert Flisiak; Philip McCloud; Nigel Pluck
Journal:  N Engl J Med       Date:  2005-06-30       Impact factor: 91.245

8.  Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.

Authors:  C Boni; A Bertoletti; A Penna; A Cavalli; M Pilli; S Urbani; P Scognamiglio; R Boehme; R Panebianco; F Fiaccadori; C Ferrari
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

Review 9.  Therapeutic vaccination in chronic hepatitis B: preclinical studies in the woodchuck model.

Authors:  M Roggendorf; I Schulte; Y Xu; M Lu
Journal:  J Viral Hepat       Date:  2007-11       Impact factor: 3.728

Review 10.  Immunomodulation as an option for the treatment of chronic hepatitis B virus infection: preclinical studies in the woodchuck model.

Authors:  Mengji Lu; Stephan Menne; Dongliang Yang; Yang Xu; Michael Roggendorf
Journal:  Expert Opin Investig Drugs       Date:  2007-06       Impact factor: 6.206
View more
  17 in total

Review 1.  New therapeutic vaccination strategies for the treatment of chronic hepatitis B.

Authors:  Jia Liu; Anna Kosinska; Mengji Lu; Michael Roggendorf
Journal:  Virol Sin       Date:  2014-01-17       Impact factor: 4.327

Review 2.  Immune therapy for hepatitis B.

Authors:  Sheikh Mohammad Fazle Akbar; Mamun Al-Mahtab; Md Sakilur Islam Khan; Ruksana Raihan; Ananta Shrestha
Journal:  Ann Transl Med       Date:  2016-09

Review 3.  The Woodchuck, a Nonprimate Model for Immunopathogenesis and Therapeutic Immunomodulation in Chronic Hepatitis B Virus Infection.

Authors:  Michael Roggendorf; Anna D Kosinska; Jia Liu; Mengji Lu
Journal:  Cold Spring Harb Perspect Med       Date:  2015-10-28       Impact factor: 6.915

4.  Novel Woodchuck Hepatitis Virus (WHV) transgene mouse models show sex-dependent WHV replicative activity and development of spontaneous immune responses to WHV proteins.

Authors:  Zhongji Meng; Zhiyong Ma; Ejuan Zhang; Anna D Kosinska; Jia Liu; Xiaoyong Zhang; Tianlun Zhou; Jun Wu; Uta Dahmen; Olaf Dirsch; Dongliang Yang; Michael Roggendorf; Mengji Lu
Journal:  J Virol       Date:  2013-11-20       Impact factor: 5.103

Review 5.  Experimental models and therapeutic approaches for HBV.

Authors:  Maura Dandri; Marc Lütgehetmann; Jörg Petersen
Journal:  Semin Immunopathol       Date:  2012-08-17       Impact factor: 9.623

6.  DNA prime-adenovirus boost immunization induces a vigorous and multifunctional T-cell response against hepadnaviral proteins in the mouse and woodchuck model.

Authors:  Anna D Kosinska; Lena Johrden; Ejuan Zhang; Melanie Fiedler; Anja Mayer; Oliver Wildner; Mengji Lu; Michael Roggendorf
Journal:  J Virol       Date:  2012-06-20       Impact factor: 5.103

Review 7.  Experimental mouse models for hepatocellular carcinoma research.

Authors:  Femke Heindryckx; Isabelle Colle; Hans Van Vlierberghe
Journal:  Int J Exp Pathol       Date:  2009-08       Impact factor: 1.925

8.  The expression of PD-1 ligands and their involvement in regulation of T cell functions in acute and chronic woodchuck hepatitis virus infection.

Authors:  Ejuan Zhang; Xiaoyong Zhang; Jia Liu; Baoju Wang; Yongjun Tian; Anna D Kosinska; Zhiyong Ma; Yang Xu; Ulf Dittmer; Michael Roggendorf; Dongliang Yang; Mengji Lu
Journal:  PLoS One       Date:  2011-10-14       Impact factor: 3.240

Review 9.  Therapeutic vaccination and immunomodulation in the treatment of chronic hepatitis B: preclinical studies in the woodchuck.

Authors:  Anna D Kosinska; Jia Liu; Mengji Lu; Michael Roggendorf
Journal:  Med Microbiol Immunol       Date:  2014-12-23       Impact factor: 3.402

10.  Combination of DNA prime--adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model.

Authors:  Anna D Kosinska; Ejuan Zhang; Lena Johrden; Jia Liu; Pia L Seiz; Xiaoyong Zhang; Zhiyong Ma; Thekla Kemper; Melanie Fiedler; Dieter Glebe; Oliver Wildner; Ulf Dittmer; Mengji Lu; Michael Roggendorf
Journal:  PLoS Pathog       Date:  2013-06-13       Impact factor: 6.823
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.